Skip to content
Companies

Etira

Oral small-molecule drugs for therapy-resistant cancers

Raised to date

$2.3M

of $3M offered across 1 Form D filing

Still open
$722K
Investors
21
Last filed
May 14, 2026

About

Etira, formerly etiraRx, is a Dallas-based clinical-stage oncology company developing small-molecule therapies for therapy-resistant and metastatic cancers. Its approach targets cancer in a way that is not dependent on how much or how often tumor cells mutate, aiming to overcome the tumor heterogeneity that defeats mutation-specific drugs. Lead candidate ERX-315 is in Phase 1 in patients with advanced, unresectable or metastatic solid tumors, with additional programs in ovarian, pancreatic and ER-positive metastatic breast cancer. The company was founded in 2018 and operates from Pegasus Park in Dallas, Texas.

Rather than targeting a specific mutation, Etira's compounds are designed to kill cancer cells regardless of how they mutate or morph, positioning them for patients whose tumors have already become resistant to standard therapy.

Funding

  • EquityFiled May 14, 2026Form D
    $2.3M/ $3M

Product

ERX-315

Clinical-stage oncology therapeutic

An investigational oral small-molecule cancer therapeutic in Phase 1, enrolling adult patients with advanced, unresectable and/or metastatic solid tumors including breast, ovarian, pancreatic and endometrial cancer and hepatocellular carcinoma, for whom standard therapies are ineffective or unavailable.

  • Phase 1 clinical stage
  • Oral small molecule
  • Targets advanced, unresectable and metastatic solid tumors

Built for

Oncologists and their patients with advanced, metastatic or therapy-resistant solid tumors, reached through clinical trial sites and ultimately pharmaceutical partners or acquirers

People on file